BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33851271)

  • 21. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
    Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
    Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of microvascular and capillary-lymphatic invasion with outcome in patients with renal cell carcinoma.
    Eisenberg MS; Cheville JC; Thompson RH; Kaushik D; Lohse CM; Boorjian SA; Costello BA; Leibovich BC
    J Urol; 2013 Jul; 190(1):37-43. PubMed ID: 23353044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcome of small, organ-confined renal cell carcinoma (RCC) is not always favourable.
    Shindo T; Masumori N; Kobayashi K; Fukuta F; Hirobe M; Tonooka A; Hasegawa T; Kitamura H; Tsukamoto T
    BJU Int; 2013 May; 111(6):941-5. PubMed ID: 23350965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.
    Xu Z; Liu Y; Yang Y; Wang J; Zhang G; Liu Z; Fu H; Wang Z; Liu H; Xu J
    Oncotarget; 2017 Jan; 8(5):7548-7558. PubMed ID: 27911274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience.
    Petros FG; Metcalfe MJ; Yu KJ; Keskin SK; Fellman BM; Chang CM; Gu C; Tamboli P; Matin SF; Karam JA; Wood CG
    World J Urol; 2018 Jul; 36(7):1093-1101. PubMed ID: 29488096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal cell carcinoma with vena caval involvement: a contemporary clinicopathologic analysis of 53 cases.
    Nwadei IU; Lorentz A; Patil D; Dimarco MA; Master VA; Osunkoya AO
    Hum Pathol; 2016 Mar; 49():83-9. PubMed ID: 26826414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score.
    Frank I; Blute ML; Cheville JC; Lohse CM; Weaver AL; Zincke H
    J Urol; 2002 Dec; 168(6):2395-400. PubMed ID: 12441925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positive Surgical Margins Increase Risk of Recurrence after Partial Nephrectomy for High Risk Renal Tumors.
    Shah PH; Moreira DM; Okhunov Z; Patel VR; Chopra S; Razmaria AA; Alom M; George AK; Yaskiv O; Schwartz MJ; Desai M; Vira MA; Richstone L; Landman J; Shalhav AL; Gill I; Kavoussi LR
    J Urol; 2016 Aug; 196(2):327-34. PubMed ID: 26907508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Female Gender Predicts Favorable Prognosis in Patients With Non-metastatic Clear Cell Renal Cell Carcinoma Undergoing Curative Surgery: Results From the International Marker Consortium for Renal Cancer (INMARC).
    Fukushima H; Saito K; Yasuda Y; Tanaka H; Patil D; Cotta BH; Patel SH; Master VA; Derweesh IH; Fujii Y
    Clin Genitourin Cancer; 2020 Apr; 18(2):111-116.e1. PubMed ID: 32001181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel prognostic model for patients with sarcomatoid renal cell carcinoma.
    Zhang BY; Thompson RH; Lohse CM; Leibovich BC; Boorjian SA; Cheville JC; Costello BA
    BJU Int; 2015 Mar; 115(3):405-11. PubMed ID: 24730416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome.
    Krejci KG; Blute ML; Cheville JC; Sebo TJ; Lohse CM; Zincke H
    Urology; 2003 Oct; 62(4):641-6. PubMed ID: 14550434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma.
    Blute ML; Itano NB; Cheville JC; Weaver AL; Lohse CM; Zincke H
    J Urol; 2003 Apr; 169(4):1276-81. PubMed ID: 12629342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive factors for late recurrence in patients with stage T1 clear cell renal cell carcinoma: a multiinstitutional study.
    Ha YS; Park YH; Kang SH; Hong SH; Hwang TK; Byun SS; Kim YJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):51-5. PubMed ID: 23017336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
    Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-11 receptor predicts post-operative clinical outcome in patients with early-stage clear-cell renal cell carcinoma.
    Pan D; Xu L; Liu H; Zhang W; Zhu Y; Xu J; Gu J
    Jpn J Clin Oncol; 2015 Feb; 45(2):202-9. PubMed ID: 25420690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positive Surgical Margins Predict Progression-free Survival After Nephron-sparing Surgery for Renal Cell Carcinoma: Results From a Single Center Cohort of 459 Cases With a Minimum Follow-up of 5 Years.
    Tellini R; Antonelli A; Tardanico R; Fisogni S; Veccia A; Furlan MC; Carobbio F; Cozzoli A; Zanotelli T; Simeone C
    Clin Genitourin Cancer; 2019 Feb; 17(1):e26-e31. PubMed ID: 30266249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Presumed radically treated renal cell carcinoma--recurrence of the disease and prognostic factors for subsequent survival.
    Beisland C; Medby PC; Beisland HO
    Scand J Urol Nephrol; 2004; 38(4):299-305. PubMed ID: 15669589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.
    Steffens S; Roos FC; Janssen M; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Junker K; Kuczyk MA; Schrader AJ;
    Virchows Arch; 2014 Oct; 465(4):439-44. PubMed ID: 25178561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of postoperative recurrence in patients with non-metastatic pT3a renal cell carcinoma.
    Ohsugi H; Ohe C; Yoshida T; Ikeda J; Sugi M; Kinoshita H; Matsuda T
    Int J Urol; 2021 Oct; 28(10):1060-1066. PubMed ID: 34346110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multi-institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy.
    Russell CM; Lebastchi AH; Chipollini J; Niemann A; Mehra R; Morgan TM; Miller DC; Palapattu GS; Hafez KS; Sexton WJ; Spiess PE; Weizer AZ
    Urology; 2018 Jul; 117():95-100. PubMed ID: 29678662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.